[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339961-105":59,"doc-detail-339961-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-microflow-cytometry-based-molecular-detection-methods-for-improved-future-mds-cancer-diagnosis-review","Advances in Microflow Cytometry-Based Molecular Detection Methods for Improved Future MDS Cancer Diagnosis - Review","","Myelodysplastic syndromes (MDS) are an early-stage blood cancer associated with progression to leukemia and other severe complications. Current diagnosis relies on blood tests, bone marrow biopsy, and genetic analysis, while flow cytometry still faces constraints in detection limit, turnaround time, and cost. The paper examines microflow cytometry advancements and their role alongside conventional diagnostic approaches for MDS and leukemia. By integrating microfluidics, portability, processing speed, and lower operating cost support microflow cytometry as a point-of-care diagnostic platform.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-microflow-cytometry-based-molecular-detection-methods-for-improved-future-mds-cancer-diagnosis-review/339961/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-microflow-cytometry-based-molecular-detection-methods-for-improved-future-mds-cancer-diagnosis-review/339961.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the main components of current MDS diagnosis described in the paper?","Question",{"text":112,"@type":113},"The paper describes MDS diagnosis using a combination of blood tests, bone marrow biopsy, and genetic analysis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What limitations motivate the use of microflow cytometry for MDS?",{"text":117,"@type":113},"Limitations include detection limit, turnaround time, and cost, which remain challenges for existing flow cytometry-based workflows.",{"name":119,"@type":110,"acceptedAnswer":120},"What advantages does microflow cytometry offer for point-of-care diagnostics?",{"text":121,"@type":113},"Microflow cytometry, integrating microfluidics, is highlighted for portability, faster processing, and reduced operating cost.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339961,1790095953,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nAdvances in Microflow Cytometry-Based Molecular Detection Methods for Improved Future MDS Cancer Diagnosis  \nMarc Gonsalves 1,2, Andres Escobar 3, Ahmad Diaa Altarabishi 3 and Chang-Qing Xu 1,3, *  \nCitation: Gonsalves, M.; Escobar, A.; Altarabishi, A.D.; Xu, C.-Q. Advancesin Microflow Cytometry-Based Molecular Detection Methods for Improved Future MDS Cancer Diagnosis. Curr. Issues Mol. Biol. 2024, 46, 8053–8070. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/cimb46080476](10.3390/cimb46080476)  \nAcademic Editors: Evangelia Stalika and Ioannis Tsamesidis  \nReceived: 9 June 2024  \nRevised: 19 July 2024  \nAccepted: 24 July 2024  \nPublished: 26 July 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Engineering Physics, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada; [gonsam2@mcmaster.ca](gonsam2@mcmaster.ca)  \n2 Faculty of Health Sciences, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada  \n3 School of Biomedical Engineering, McMaster University, 1280 Main Street West, Hamilton, ON L8S 4L8, Canada; [escoba3@mcmaster.ca](escoba3@mcmaster.ca) (A.E.); [altaraba@mcmaster.ca](altaraba@mcmaster.ca) (A.D.A.)  \n* Correspondence: [cqxu@mcmaster.ca](cqxu@mcmaster.ca)  \nAbstract: Myelodysplastic syndromes (MDS) are a rare form of early-stage blood cancer that typically leads to leukemia and other deadly complications. The typical diagnosis for MDS involves a mixture of blood tests, a bone marrow biopsy, and genetic analysis. Flow cytometry has commonly been used to analyze these types of samples, yet there still seems to be room for advancement in several areas, such as the limit of detection, turnaround time, and cost. This paper explores recent advancements in microflow cytometry technology and how it may be used to supplement conventional methods of diagnosing blood cancers, such as MDS and leukemia, through flow cytometry. Microflow cytometry, a more recent adaptation of the well-researched and conventional flow cytometry techniques, integrated with microfluidics, demonstrates significant potential in addressing many of the shortcomings flow cytometry faces when diagnosing a blood-related disease such as MDS. The benefits that this platform brings, such as portability, processing speed, and operating cost, exemplify the importance of exploring microflow cytometry as a point-of-care (POC) diagnostic device for MDS and other forms of blood cancer.  \nKeywords: microfluidics; diagnostics; MDS; flow cytometry; microflow cytometry  \n1. Introduction  \nCancer remains one of the most prolific and widespread causes of death across the globe. The World Health Organization (WHO) estimated the number of new cancer cases in 2022 to be 20 million people worldwide, while expecting the number to rise to a staggering 35 million by 2050—a 77% increase [1] . Early detection and treatment of cancers has been an effective tool in successfully treating cancers into remission. However, this process is plagued by limitations in diagnostic technique specificity, sensitivity, and turnaround time, as well as patient safety concerns. Historically, commonplace diagnostic techniques such as low dose computed tomography (LDCT), mammography, magnetic resonance imaging (MRI), and sputum cytology were used to try and detect and diagnose cancers in conjunction with one another. However, due to some of the inherent limitations associated with these diagnostic methods, such as cost, specificity, and detection limits, their diagnostic potential was left somewhat wanting [2,3] . Over time, to try and address these limitations, a more recent technological advancement known ","cbCaimsNBvmCCREe","https://ap.wps.com/l/cbCaimsNBvmCCREe","pdf",2710950,18,"English","# Introduction\n## Microflow cytometry and flow cytometry background\n# Conventional flow cytometry principles\n## Optical and scattering parameters","[{\"question\":\"What are the main components of current MDS diagnosis described in the paper?\",\"answer\":\"The paper describes MDS diagnosis using a combination of blood tests, bone marrow biopsy, and genetic analysis.\"},{\"question\":\"What limitations motivate the use of microflow cytometry for MDS?\",\"answer\":\"Limitations include detection limit, turnaround time, and cost, which remain challenges for existing flow cytometry-based workflows.\"},{\"question\":\"What advantages does microflow cytometry offer for point-of-care diagnostics?\",\"answer\":\"Microflow cytometry, integrating microfluidics, is highlighted for portability, faster processing, and reduced operating cost.\"}]","Advances in Microflow Cytometry-Based Molecular Detection Methods for Improved Future MDS Cancer Diagnosis - Review | PDF",1790033354,45]